Novel ERbeta agonists for the treatment of gliomas
用于治疗神经胶质瘤的新型 ERbeta 激动剂
基本信息
- 批准号:9326814
- 负责人:
- 金额:$ 31.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-01 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAgonistApoptosisBiologicalBiological AssayBlood - brain barrier anatomyBrainBrain NeoplasmsCell Cycle ProgressionCell ProliferationCellsCentral Nervous System NeoplasmsClinicalClinical TrialsDevelopmentEpidemiologyEstrogen Receptor alphaEstrogen Receptor betaEstrogensGene ExpressionGenomicsGlioblastomaGliomaGlycyrrhizaGlycyrrhiza uralensisGoalsGrowthHot flushesIn VitroInflammationInflammatoryLigand Binding DomainLigandsMalignant - descriptorMalignant NeoplasmsMediatingMolecularNeuronsNuclearPathway interactionsPatientsPermeabilityPhasePlantsPlayPrimary Brain NeoplasmsProtein IsoformsRadiationRadiation therapyResearchRoleSamplingSchizophreniaSignal TransductionStem cellsSymptomsTestingTherapeuticTherapeutic AgentsTimeTissuesToxic effectTranslatingTreatment EfficacyTumor PromotersTumor SuppressionTumor Suppressor ProteinsVasomotorXenograft procedurechemotherapyequolin vivoinnovationinsightnovelnovel drug classnovel therapeuticsprognostic significancepublic health relevancesoystem cell differentiationtooltumor
项目摘要
DESCRIPTION (provided by applicant): Glioblastoma (GBM) are the most malignant primary brain tumor and patients with GBM (grade IV glioma) have a survival time of approximately 14 months. Estrogen plays a crucial role during brain development and differentiation. Epidemiological and experimental evidence suggests tumor suppressive role of estrogen on brain tumors. However, the molecular mechanisms by which estrogen mediate protection against GBM remains unknown. Estrogen functions are mediated by two ER-subtypes: ER� that functions as tumor promoter and ER� that functions as a tumor suppressor. Emerging evidence suggest that GBM cells express ER�; however, the clinical utility of ER� is limited due to lack of mechanistic insights and agents that specifically target ER�. Recent studies have identified liquiritigenin (LIQ) isolated from the plant Glycyrrhiza uralensis and synthetic compound LY500307 (LY) as selective ER� specific agonists. The objective of this proposal is to translate evolving scientific evidence and the functional role of ER� into a clinical strategy to suppress GBM by employing ER� specific agonists. Our central hypothesis is that ER� agonists inhibit the growth of GBM by enhancing tumor suppressive functions of ER� and that ER� agonists promote differentiation of glioma stem cells leading to increased therapeutic efficacy. The hypothesis is supported by our preliminary studies that (1) ER�-mediated mechanisms play a tumor suppressive function; (2) ER� agonists suppress GBM cell proliferation in vitro and in vivo; (3) ER�-agonists upregulate expression of ER� (4) ER�-agonists inhibit growth of Glioma Stem Cells and promote their differentiation. To investigate the proposed hypotheses, in aim 1, we will test the significance and therapeutic efficacy of ER� agonists to inhibit the growth of GBM. In aim 2, we will determine the molecular mechanism(s) of ER� agonists in the suppression of GBM. In aim 3, we will investigate the role of ER� agonists in the differentiation of Glioma Stem Cells. Understanding how ER� functions as a tumor suppressor in GBM will be useful in maximizing treatment opportunities for GBM. The proposed research is innovative due to the novelty of the concepts involving ER� agonists and their therapeutic potential in the suppression of GBM. This proposal will establish the significance and therapeutic potential of ER� signaling in GBM progression and thus create a new paradigm for the use of ER� specific ligands (LIQ and LY) for curbing GBM progression. Since ER� agonists currently in clinical trials are well tolerated with limited side effects and good blood-brain barrier permeability, identification of ER� agonists as a therapeutic agent can be readily adapted to clinical use as a monotherpy or in combination with current chemotherapies and radiation, thereby providing an additional tool for enhancing survival in GBM patients. Further, the results from these studies have the potential to provide novel insights into the mechanisms of ER� mediated tumor suppression at the molecular level.
描述(申请人提供):胶质母细胞瘤(GBM)是最恶性的原发脑肿瘤,GBM(IV级胶质瘤)患者的生存时间约为14个月。雌激素在大脑发育和分化过程中起着至关重要的作用。流行病学和实验证据表明,雌激素对脑肿瘤具有肿瘤抑制作用。然而,雌激素介导对GBM的保护的分子机制仍不清楚。雌激素的作用由两种ER亚型介导:作为肿瘤促进剂的ER�和作为肿瘤抑制因子的ER�。新的证据表明,基底膜细胞表达ER�;然而,由于缺乏针对ER�的机械性见解和药物,ER�的临床应用受到限制。最近的研究发现,从植物甘草中分离得到的甘草素(LIQ)和合成的化合物LY500307(LY)是选择性ER�特异性激动剂。该建议的目的是将不断发展的科学证据和ER�的功能作用转化为一种临床策略,通过使用ER�特异性激动剂来抑制基底膜。我们的中心假设是ER�激动剂通过增强ER�的肿瘤抑制功能来抑制基底膜的生长,ER�激动剂促进胶质瘤干细胞的分化,从而提高治疗效果。我们的初步研究支持这一假说:(1)ER�介导的机制发挥肿瘤抑制作用;(2)ER�激动剂在体内外抑制基底细胞增殖;(3)ER�激动剂上调ER�的表达;(4)ER�激动剂抑制胶质瘤干细胞的生长并促进其分化。为了验证提出的假设,在目标1中,我们将测试ER�激动剂抑制基底膜生长的意义和治疗效果。在目标2中,我们将确定ER�激动剂抑制基底膜的分子机制(S)。在目标3中,我们将研究ER�激动剂在胶质瘤干细胞分化中的作用。了解ER�在基底膜中作为肿瘤抑制因子的作用,将有助于最大限度地增加基底膜的治疗机会。这项拟议的研究具有创新性,因为涉及ER�激动剂的概念及其在抑制基底膜方面的治疗潜力具有新颖性。这一建议将确立ER�信号在基底膜进展中的意义和治疗潜力,从而为使用ER�特异性配体(LIQ和LY)抑制基底膜进展创造一个新的范例。由于目前在临床试验中的ER�激动剂耐受性良好,副作用有限,且具有良好的血脑屏障通透性,因此将ER�激动剂鉴定为治疗剂可以很容易地适应临床使用,或者与目前的化疗和放射治疗相结合,从而为提高基底膜患者的存活率提供另一种工具。此外,这些研究的结果有可能在分子水平上为ER�介导的肿瘤抑制机制提供新的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Jacob Brenner其他文献
Andrew Jacob Brenner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Jacob Brenner', 18)}}的其他基金
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma
开发用于治疗胶质母细胞瘤的有效雌激素受体β激动剂
- 批准号:
10594832 - 财政年份:2023
- 资助金额:
$ 31.02万 - 项目类别:
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma
铼纳米脂质体 (RNL186) 治疗胶质母细胞瘤的临床开发
- 批准号:
10242665 - 财政年份:2019
- 资助金额:
$ 31.02万 - 项目类别:
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma
铼纳米脂质体 (RNL186) 治疗胶质母细胞瘤的临床开发
- 批准号:
10013171 - 财政年份:2019
- 资助金额:
$ 31.02万 - 项目类别:
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma
铼纳米脂质体 (RNL186) 治疗胶质母细胞瘤的临床开发
- 批准号:
10687851 - 财政年份:2019
- 资助金额:
$ 31.02万 - 项目类别:
Omega-3 Fatty Acid Modulation of Obesity-Induced Aromatase Expression
Omega-3 脂肪酸对肥胖诱导的芳香酶表达的调节
- 批准号:
9035932 - 财政年份:2015
- 资助金额:
$ 31.02万 - 项目类别:
Omega-3 Fatty Acid Modulation of Obesity-Induced Aromatase Expression
Omega-3 脂肪酸对肥胖诱导的芳香酶表达的调节
- 批准号:
9198761 - 财政年份:2015
- 资助金额:
$ 31.02万 - 项目类别:
Novel ERbeta agonists for the treatment of gliomas
用于治疗神经胶质瘤的新型 ERbeta 激动剂
- 批准号:
8762188 - 财政年份:2014
- 资助金额:
$ 31.02万 - 项目类别:
Phase 2 Study of TH-302 for the Treatment of Glioblastoma
TH-302 治疗胶质母细胞瘤的 2 期研究
- 批准号:
8748318 - 财政年份:2014
- 资助金额:
$ 31.02万 - 项目类别:
Phase 2 Study of TH-302 for the Treatment of Glioblastoma
TH-302 治疗胶质母细胞瘤的 2 期研究
- 批准号:
9108161 - 财政年份:2014
- 资助金额:
$ 31.02万 - 项目类别:
Phase 2 Study of TH-302 for the Treatment of Glioblastoma
TH-302 治疗胶质母细胞瘤的 2 期研究
- 批准号:
9316339 - 财政年份:2014
- 资助金额:
$ 31.02万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 31.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 31.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 31.02万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 31.02万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 31.02万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 31.02万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 31.02万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 31.02万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 31.02万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 31.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)